Electronic skin nanopatches for continuous blood pressure monitoring. Electronic skin nanopatches for continuous blood pressure monitoring. This project aims to develop soft, thin, wearable and non-invasive heart health monitors that continuously monitor blood pressures anytime anywhere, using an electronic skin technology platform with the world’s thinnest gold nanowires. Nanotechnologists, electrical engineers, clinicians, information technologists and industrial designers will collaborate to ....Electronic skin nanopatches for continuous blood pressure monitoring. Electronic skin nanopatches for continuous blood pressure monitoring. This project aims to develop soft, thin, wearable and non-invasive heart health monitors that continuously monitor blood pressures anytime anywhere, using an electronic skin technology platform with the world’s thinnest gold nanowires. Nanotechnologists, electrical engineers, clinicians, information technologists and industrial designers will collaborate to develop blood pressure correlation algorithms and evaluate sensing performances. New knowledge and commercial technologies will make Australian medical technology industries competitive global leaders in wearable technology industries.Read moreRead less
Early Career Industry Fellowships - Grant ID: IE230100564
Funder
Australian Research Council
Funding Amount
$353,258.00
Summary
On-Site, Reponsive and Less Invasive Drug Testing In Corrective Services. This project aims to develop a new drug screening system using nanomaterials interfaced with advanced mass spectrometry to improve testing speed, cost, and accuracy, and minimise the distress associated with current drug testing programs within corrective services. Currently, testing programs are costly, with confirmation taking multiple weeks, preventing appropriate responses to drug use and support service recommendation ....On-Site, Reponsive and Less Invasive Drug Testing In Corrective Services. This project aims to develop a new drug screening system using nanomaterials interfaced with advanced mass spectrometry to improve testing speed, cost, and accuracy, and minimise the distress associated with current drug testing programs within corrective services. Currently, testing programs are costly, with confirmation taking multiple weeks, preventing appropriate responses to drug use and support service recommendations. Additionally, vulnerable people in custody or on corrective orders find conventional urine testing distressing, especially when previously exposed to sexual violence. New accurate, rapid saliva testing on-site will revolutionise drug monitoring and provide an Australian designed solution for correctional jurisdictions. Read moreRead less
A Nano-platform for affordable and ultra-sensitive bio-marker detection. This project aims to develop a next-generation nano-platform and lateral flow assays (LFA) device for ultra-sensitive detection of biomarkers. LFA’s are used for the rapid detection of biomarkers; however, their sensitivity is relatively low. The preparation of innovative porous silica nanoparticles with uniform particle size and controllable structures (pore size, pore structure, internal surface functionality and density ....A Nano-platform for affordable and ultra-sensitive bio-marker detection. This project aims to develop a next-generation nano-platform and lateral flow assays (LFA) device for ultra-sensitive detection of biomarkers. LFA’s are used for the rapid detection of biomarkers; however, their sensitivity is relatively low. The preparation of innovative porous silica nanoparticles with uniform particle size and controllable structures (pore size, pore structure, internal surface functionality and density) will enable higher loading of quantum dots and enhanced detection sensitivity. Improving the detection sensitivity of the inexpensive and disposable LFA diagnostic technology will open up new applications for rapid and accurate biomarker detection. The resulting technology will advance Australian industrial capability and competiveness in the global lateral flow assays market, which is estimated to be valued at US$ 6.78 billion by 2020.Read moreRead less